LOGIN  |  REGISTER
Cue Biopharma

VitalHub Benefitting From Recent UK Government Initiatives

January 08, 2024 | Last Trade: C$11.10 0.05 -0.45

TORONTO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) is pleased to announce the United Kingdom (UK) government’s investment in System Coordination Centre (SCC) medical technology, aimed at alleviating the capacity strain on the NHSE (National Health Service England). VitalHub’s SHREWD technology platform provides an operational situation dashboard, which is being incorporated into Integrated Care Systems (ICSs). This system will generate proactive alerts, enhancing the quality and longevity of health and care services for local communities.

In the UK, 42 Integrated Care Systems (ICSs) operate as partnerships uniting together NHSE, local health, and care organizations. Together they develop plans to improve the long-term health and care services for people and communities. Acknowledged as the future of health and care integration, ICSs play a pivotal role in both the NHSE Long Term Plan and Health and Care Act, according to NHSE leaders.

System Coordination Centres (SCCs) play a crucial role in ensuring the highest quality of care across all health disciplines. They manage clinical risk within and across acute, community, mental health, primary care, and social care services while overseeing system demand, capacity, and risk mitigation. Recent new funding is earmarked to enhance patient care, reduce waiting lists, expedite diagnoses, and introduce innovative methods for treating patients. It will also encourage the adoption of technologies such as virtual wards for remote patient care and wearable devices for monitoring chronic conditions from the comfort of one's home.

"We are extremely pleased to be directly benefiting from the contribution of the UK government’s ongoing commitment to provide best in class healthcare. This program will support key NHS priorities to address the requirements of ICS to have Smart System Control implemented as a SCC,” commented Dan Matlow, CEO of VitalHub. “We are delighted to support this region through our world class SHREWD suite of offerings. SHREWD operational situation dashboards allow users to easily identify where local urgent care system pressures are developing, and to act through proactive alerts, inbuilt teleconferencing and paperless audit systems. We view this investment as furtherance to the growing opportunities we enjoy in markets for our products and our market-leading position.”

ABOUT VITALHUB

Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.

VitalHub Corp. (the “Company” or “VitalHub”) provides technology to Health and Human Services providers including Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination & Optimization, and Patient Flow & Operational Visibility solutions.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive merger and acquisition (“M&A”) plan. Currently VitalHub serves more than 1,000 clients across Canada, USA, UK, Australia, the Middle East, and Europe.

VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 350 team members globally. The Company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on the OTC Markets OTCQX Exchange under the symbol “VHIBF”.

CAUTIONARY STATEMENT

Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB